What is ELDN (ELDN) stock price today?

ELDN (ELDN) is currently trading at $3.01, up 1.01% today.

What is ELDN P/E ratio?

ELDN's P/E ratio is -4.85. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is ELDN return on equity (ROE)?

ELDN's return on equity (ROE) is -72.68%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is ELDN's market cap?

ELDN has a market capitalization of $232.34M.

NASDAQ · Biotechnology

ELDN (ELDN) Stock

$3.01 +1.01% NASDAQ: ELDN Healthcare

Valuation

Metric	Value
Price	$3.01
Market Cap	$232.34M
P/E Ratio	-4.85
P/B Ratio	2.65
P/S Ratio	0.00
EPS (TTM)	$-0.80
52-Week High	$4.60
52-Week Low	$1.35
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-72.68%
ROA	-35.09%
ROCE	-102.47%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.01
Current Ratio	7.56

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-37.0M	$-88.0M	$-43.0M	$-71.0M	$-83.0M
Net Profit	$-35.0M	$-88.0M	$-117.0M	$-36.0M	$-46.0M
EPS	$-2.33	$-6.16	$-4.73	$-0.75	$-0.56
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$171.0M	$93.0M	$89.0M	$177.0M	$169.0M
Total Liabilities	$7.0M	$9.0M	$82.0M	$59.0M	$88.0M
Cash	$85.0M	$56.0M	$5.0M	$21.0M	$23.0M
Borrowings	$1.0M	$1.0M	$0	$1.0M	$1.0M

Latest News

NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board GlobeNewswire · Jul 8, 2026 NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes GlobeNewswire · Jul 1, 2026 Natera, Eledon Partner to Use Prospera in Phase 3 Kidney Transplant Trial MT Newswires · Jun 25, 2026 Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial Business Wire · Jun 25, 2026 Eledon Says Mid-Stage Data Shows Tegoprubart Offers Higher Kidney Function, Improved Outcomes Compared with Tacrolimus MT Newswires · Jun 22, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-29.0M	$-28.0M	$-40.0M	$-47.0M	$-62.0M
Investing Cash Flow	$0	$0	$-45.0M	$-70.0M	$11.0M
Financing Cash Flow	$0	$0	$0	$0	$0
Net Cash Flow	$-29.0M	$-28.0M	$-52.0M	$16.0M	$2.0M
Free Cash Flow	$-29.0M	$-28.0M	$-40.0M	$-47.0M	$-62.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-32.74%
Quick Ratio	8.44
Interest Coverage	—
Return 1Y	-1.84%
Return 3Y	187.69%
Return 5Y	-43.28%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ABEO	$5.98	+2.22%	5.14	$340.83M	0.00%
ACHV	$8.25	+3.90%	-4.63	$846.94M	0.00%
ALLO	$1.99	-0.75%	-2.17	$685.13M	0.00%
AVIR	$5.49	+2.62%	-2.13	$439.35M	0.00%
EDIT	$3.07	+0.33%	-1.39	$471.13M	0.00%

About ELDN

ELDN is led by CEO David-Alexandre C. Gros, employs 31 people, headquartered in US, publicly traded since 2014.

ELDN stock trades at $3.01 with a market capitalization of $232.34M. The stock is valued at a price-to-earnings (P/E) ratio of -4.85, price-to-book of 2.65, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.35 and $4.60, and currently trades 34.6% below its 52-week high.

On profitability, ELDN generates a return on equity (ROE) of -72.68%, return on capital employed of -102.47%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides